Labor market affiliation of patients with myeloproliferative neoplasms: a population-based matched cohort study

  • Lise Skovgaard Svingel (Creator)
  • Sarah Friis Christensen (Creator)
  • Anders Kjærsgaard (Aarhus University) (Creator)
  • Anna Stenling (Creator)
  • Björn Paulsson (Creator)
  • Christen Lykkegaard Andersen (Creator)
  • Christian Fynbo Christiansen (Aarhus University) (Creator)
  • Jesper Stentoft (Creator)
  • Jørn Starklint (Creator)
  • Marianne Tang Severinsen (Creator)
  • Mette Borg Clausen (Contributor)
  • Morten Hagemann Hilsøe (Contributor)
  • Hans Carl Hasselbalch (Creator)
  • Henrik Frederiksen (Creator)
  • Marie Bak (Creator)
  • Ellen Margrethe Mikkelsen (Creator)

Dataset

Description

Patients with myeloproliferative neoplasms (MPNs) suffer from substantial symptoms and risk of debilitating complications, yet observational data on their labor market affiliation are scarce. We conducted a descriptive cohort study using data from Danish nationwide registries, including patients diagnosed with MPN in 2010-2016. Each patient was matched with up to ten comparators without MPN on age, sex, level of education, and region of residence. We assessed pre- and post-diagnosis labor market affiliation, defined as working, unemployed, or receiving sickness benefit, disability pension, retirement pension, or other health-related benefits. Labor market affiliation was assessed weekly from two years pre-diagnosis until death, emigration, or 31 December 2018. For patients and comparators, we reported percentage point (pp) changes in labor market affiliation cross-sectionally from week −104 pre-diagnosis to week 104 post-diagnosis. The study included 3,342 patients with MPN and 32,737 comparators. From two years pre-diagnosis until two years post-diagnosis, a larger reduction in the proportion working was observed among patients than comparators (essential thrombocythemia: 10.2 [95% CI: 6.3–14.1] vs. 6.8 [95% CI: 5.5–8.0] pp; polycythemia vera: 9.6 [95% CI: 5.9–13.2] vs. 7.4 [95% CI: 6.2–8.7] pp; myelofibrosis: 8.1 [95% CI: 3.0–13.2] vs. 5.8 [95% CI: 4.2–7.5] pp; and unclassifiable MPN: 8.0 [95% CI: 3.0–13.0] vs. 7.4 [95% CI: 5.7–9.1] pp). Correspondingly, an increase in the proportion of patients receiving sickness benefits including other health-related benefits was evident around the time of diagnosis. Overall, we found that Danish patients with essential thrombocythemia, polycythemia vera, myelofibrosis, and unclassifiable MPN had slightly impaired labor market affiliation compared with a population of the same age and sex. From two years pre-diagnosis to two years post-diagnosis, we observed a larger reduction in the proportion of patients with MPN working and a greater proportion receiving sickness benefits compared with matched individuals.
Date made available2023
PublisherTaylor & Francis

Cite this